{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-23-001806","form_type":"8-K","ticker":"PMDI","cik":"0000806517","company_name":"PSYCHEMEDICS CORP","filed_at":"2023-03-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:48.135225+00:00","generated_at":"2026-06-17T22:40:30.323693+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Psychemedics reports flat FY2022 revenue; net loss widens to $0.19/sh; declares $0.07 dividend","bullets":["FY2022 revenue $25.2M (+1% YoY); net loss $1.1M or ($0.19) diluted EPS vs loss $0.7M ($0.12) prior year.","Q4 2022 revenue $5.7M (-11% YoY); net loss $0.7M or ($0.12) diluted EPS vs loss $1.6M ($0.29).","Board declared $0.07 quarterly cash dividend, payable April 10, 2023 to holders of record March 31, 2023.","Cash $4.8M, working capital $4.3M at year-end; equipment financing reduced to $0.6M.","Management cites labor shortage and inflation challenges; domestic revenue up 4% in 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-23-001806","json":"https://secwatch.observer/filing/0001171843-23-001806.json","markdown":"https://secwatch.observer/filing/0001171843-23-001806.md","text":"https://secwatch.observer/filing/0001171843-23-001806.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/806517/000117184323001806/0001171843-23-001806-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/806517/000117184323001806/f8k_032123.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T22:40:30.323693+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5a16209b815267270605773f091f5af85dbd767f","claim":"PSYCHEMEDICS CORP reported the quarter ended December 31, 2022 results: revenue $5.7 million, net income $0.7 million, EPS ($0.12) per diluted share.","evidence_excerpt":"The Company’s revenue for the quarter ended December 31, 2022, was $5.7 million versus $6.4 million for the quarter ended December 31, 2021, a decrease of 11%. Net loss for the quarter ended December 31, 2022, was $0.7 million or ($0.12) per diluted share, versus net loss of $1.6 million or ($0.29) per diluted share, for the comparable period last year.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/806517/000117184323001806/0001171843-23-001806-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended December 31, 2022"},{"label":"Revenue","value":"$5.7 million"},{"label":"Net income","value":"$0.7 million"},{"label":"EPS","value":"($0.12) per diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"8d0973862a04cacb2c6a99cfca2b0e3acebc15b4","claim":"PSYCHEMEDICS CORP reported the year ended December 31, 2022 results: revenue $25.2 million, net income $1.1 million, EPS ($0.19) per diluted share.","evidence_excerpt":"The Company's revenue for the year ended December 31, 2022, was $25.2 million versus $24.9 million for the year ended December 31, 2021, an increase of 1%. Net loss for the year ended December 31, 2022, was $1.1 million or ($0.19) per diluted share, versus net loss of $0.7 million or ($0.12) per diluted share, for the comparable period last year.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/806517/000117184323001806/0001171843-23-001806-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2022"},{"label":"Revenue","value":"$25.2 million"},{"label":"Net income","value":"$1.1 million"},{"label":"EPS","value":"($0.19) per diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}